News & Analysis on Clinical Trial Services & Contract Research And Development
Speciality chemicals group Noviant has developed a certified GM-free disintegrant for use in tablets, allowing supplement makers to continue supplying a full range of products without having to add labels required under new European laws.
Life sciences company Tepnel has signed a conditional agreement to acquire OpiSAS' (Opi) subsidiary Diaclone Research, a company that produces monoclonal antibodies for in vitro studies and diagnostic purposes.
Dowpharma has announced plans to close its biopharmaceutical contract manufacturing facility in Smithfield, Rhode Island.
A German partnership is making headway on what could be the first genetically engineered drug made from a vegetable substance.
A unique approach to microdosing, providing drug data ahead of schedule and with improved accuracy, could herald a new era in drug development in which human ADME data is involved in candidate selection or deselection.
Despite Thermo Electron reporting a Q2 revenue growth of 12 per cent, organic revenue growth declined from 5 per cent in 1Q04 to 3 per cent in the second quarter, due in part to the company's sale of its Optical Technologies division.
The first grants given in the UK for drug development in early phase clinical experiments have been awarded to gene therapy trials that may herald a breakthrough in intra-abdominal cancer which has an average survival rate of less than 12 months.
A potential new drug target for treatment of cancer has amazed scientists who believe it plays such a key role in preventing cancer onset that it opens up a range of different targeting options for multiple types of cancer.